🇺🇸 NBIX — Neurocrine Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

159,76 USD

Máx. histórico

185,50

98 días

Caída desde máximo

-13,88%

Rango 52 semanas

122,14 – 186,12

Variación hoy

-3,79%

Cierre anterior

166,05

Rango de hoy

159,53 – 167,68

Volumen hoy

1.482.485

Peor caída histórica

-97,21%

15/03/2006 → 12/11/2009

Recuperado en 2911 días

Volatilidad anualizada ⓘ

61,30%

Información
Nombre completo
Neurocrine Biosciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
2.500
PER ⓘ
23,70 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
207,50 USD (puede no estar actualizado)
Primera cotización
23/05/1996
Precio actualizado
hace 12 horas
Sobre la empresa

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
06/02/2024 141,96 143,16 140,87 142,96 +0,92% 1,61% 1.034.100
05/02/2024 141,18 141,97 139,72 141,66 -0,06% 1,59% 672.700
02/02/2024 142,73 142,91 141,06 141,74 -0,50% 1,30% 395.800
01/02/2024 139,77 142,69 138,43 142,45 +1,92% 3,05% 858.400
31/01/2024 141,94 142,22 139,43 139,77 -1,61% 1,97% 1.148.500
30/01/2024 142,50 143,00 141,68 142,06 -0,11% 0,93% 474.600
29/01/2024 142,30 143,35 141,89 142,22 +0,05% 1,03% 597.800
26/01/2024 141,73 142,75 140,81 142,15 +0,81% 1,37% 716.600
25/01/2024 141,02 141,27 139,17 141,01 +0,64% 1,49% 585.000
24/01/2024 141,18 141,65 139,84 140,11 -0,21% 1,28% 637.600
23/01/2024 140,11 140,71 139,10 140,41 +0,44% 1,15% 803.000
22/01/2024 138,50 140,30 137,22 139,80 +1,77% 2,22% 834.300
19/01/2024 137,12 137,94 136,05 137,37 +0,45% 1,38% 636.800
18/01/2024 137,40 139,56 136,00 136,75 -0,27% 2,59% 993.400
17/01/2024 132,71 137,19 131,85 137,12 +3,39% 4,02% 1.100.400
16/01/2024 130,95 132,72 130,16 132,62 +0,45% 1,95% 705.700
12/01/2024 130,74 132,55 130,00 132,03 +1,11% 1,95% 573.200
11/01/2024 131,15 131,71 129,50 130,58 -1,37% 1,69% 604.500
10/01/2024 134,52 134,74 131,65 132,39 -0,99% 2,30% 623.400
09/01/2024 133,96 134,93 132,26 133,71 -0,17% 1,99% 467.200
08/01/2024 131,23 134,05 129,81 133,94 +1,10% 3,23% 762.000
05/01/2024 132,80 133,54 131,01 132,48 -0,82% 1,91% 824.100
04/01/2024 132,92 134,28 132,92 133,58 +0,64% 1,02% 782.300
03/01/2024 131,91 133,67 130,85 132,73 +0,76% 2,14% 623.000
02/01/2024 130,20 133,33 130,15 131,73 -0,02% 2,44% 767.800
29/12/2023 132,13 133,28 131,01 131,76 -0,30% 1,72% 671.200
28/12/2023 132,64 133,64 132,10 132,15 -0,46% 1,16% 510.100
27/12/2023 131,15 132,98 130,89 132,76 +1,20% 1,59% 576.400
26/12/2023 128,84 131,47 128,00 131,19 +2,13% 2,69% 667.300
22/12/2023 122,89 130,84 122,89 128,45 +6,02% 6,47% 2.155.200